Adam Cheifetz

Dr. Cheifetz is Director of the Center for Inflammatory Bowel Disease and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology Clerkship Elective and Associate Director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center.
Dr. Cheifetz specializes in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published over 250 articles and chapters on the subject. His research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care. Dr. Cheifetz lectures nationally and internationally on IBD. Dr. Cheifetz is also actively involved in teaching and mentoring medical students, residents, and fellows, and is proud to have trained numerous physicians who now specialize in IBD and direct their own centers.

David Choi completed his Doctor of Pharmacy degree at the University of Colorado School of Pharmacy. He went on to complete his PGY1 Pharmacy Residency and PGY2 Ambulatory residency at The Johns Hopkins Hospital. He is currently an Associate Director at University of Chicago Medicine Inflammatory Bowel Disease Center. He is very excited about advocating for increased pharmacists’ role in gastroenterology/hepatology as well as importance for patient advocacy in receiving the care they require. He feels passionately about treat to target to improve patient care and research related to improving patient outcomes.

Dr. Cheifetz is Director of the Center for Inflammatory Bowel Disease and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology Clerkship Elective and Associate Director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center.
Dr. Cheifetz specializes in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published over 250 articles and chapters on the subject. His research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care. Dr. Cheifetz lectures nationally and internationally on IBD. Dr. Cheifetz is also actively involved in teaching and mentoring medical students, residents, and fellows, and is proud to have trained numerous physicians who now specialize in IBD and direct their own centers.

Parambir S. Dulai, MD, is a board-certified gastroenterologist with clinical and research expertise in inflammatory bowel disease (IBD). Dr. Dulai is a proud recipient of the 2022 Sherman Emerging Leader Prize by The Bruce and Cynthia Sherman Charitable Foundation that recognizes outstanding achievements in IBD. He is an Associate Professor of Medicine at Northwestern University where he also serves as Director of Precision Medicine for the Division of Gastroenterology and Hepatology. Dr. Dulai completed his medical school training at Dayanand Medical College in Ludhiana, Punjab, India, and subsequently completed his internal medicine residency and chief residency at Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. He then went on to complete an NIH sponsored T32 research fellowship and IBD clinical fellowship at the University of California San Diego, La Jolla, CA, USA. He spent an additional year of advanced training in clinical trials with Robarts Clinical Trials and in 2019 he was the recipient of the American Gastroenterology Association (AGA) research scholar award focused on personalized medicine. He has a successful NIH funded research program focused on real world evidence generation, clinical trials, and integrating evolving translational technology into mechanism of action studies.

Dr. Cheifetz is Director of the Center for Inflammatory Bowel Disease and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology Clerkship Elective and Associate Director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center.
Dr. Cheifetz specializes in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published over 250 articles and chapters on the subject. His research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care. Dr. Cheifetz lectures nationally and internationally on IBD. Dr. Cheifetz is also actively involved in teaching and mentoring medical students, residents, and fellows, and is proud to have trained numerous physicians who now specialize in IBD and direct their own centers.

Dr. Bridget E. Shields is the Susan Nicholas Fasciano Family Foundation Professor of Inflammatory Skin Diseases, Associate Professor, and Director of the Clinical and Translational Research Program in the Department of Dermatology at the University of Wisconsin–Madison. She completed her dermatology residency at the University of Wisconsin, where she served as Chief Resident, followed by a fellowship in Complex Medical Dermatology at the University of Pennsylvania with specialized training in granulomatous skin diseases, including cutaneous Crohn disesae. Dr. Shields directs the University of Wisconsin's specialized IBD-Dermatology clinic and serves on the inpatient dermatology consultation service, caring for patients with complex inflammatory skin disorders. She also leads the University of Wisconsin Multidisciplinary Sarcoidosis Program, fostering collaboration among clinicians and scientists to improve the understanding and treatment of systemic granulomatous disease.
As a clinician-scientist, Dr. Shields' research focuses on defining the molecular mechanisms underlying skin manifestations of IBD through spatial transcriptomics, multiomics, and translational immunology, with the goal of developing precision diagnostics and targeted therapies.
Dr. Shields has authored more than 70 peer-reviewed scientific publications and numerous invited book chapters. She is a nationally recognized speaker who has delivered invited lectures on skin manifestations of IBD and other inflammatory dermatologic disorders at regional and national scientific meetings.
Her research program has been supported by the Dermatology Foundation Medical Dermatology Career Development Award and the Ann Theodore Foundation, among other competitive funding sources.

Oriana M. Damas, MD, MSCTI, is an Associate Professor of Medicine at the University of Miami Miller School of Medicine. She also serves as the Director of Translational Studies for the Crohn’s and Colitis Center. Dr. Damas earned her medical degree from the University of Miami and completed her training in internal medicine and gastroenterology at the University of Miami and Jackson Memorial Hospital.

Her clinical practice and research focus on the care of patients with inflammatory bowel disease (IBD). Dr. Damas has conducted extensive research on environmental factors and the epidemiology of IBD. Her contributions to the field have earned her accolades, including the DREAM Award in recognition of her work with the Hispanic IBD community.

Dr. Damas has significant experience in running clinical trials, including innovative dietary trials, aimed at improving the quality of life for patients with IBD through lifestyle and dietary modifications. She is an NIH-funded researcher and currently serves as the principal investigator for a study developing an anti-inflammatory South Florida diet for IBD patients, which incorporates elements of traditional Latin foods from the region.

She has authored numerous original research articles, and she serves on the Editorial Boards of the prestigious Gastroenterology journal and Crohn’s & Colitis 360. In addition to her research, Dr. Damas is recognized as a national and international leader in her field. She is frequently invited to speak at national and international conferences and is an active member of the AGA n and the Crohn’s & Colitis Foundation.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Jason Schairer is the Director of the Henry Ford IBD Center in Michigan. His interests include Interventional IBD with a focus on stricturotomy, addressing health care inequity, intimacy and sex in IBD, and improving medical education for providers of all levels. He received his medical degree from Wayne Statue University, and went on to complete a fellowship in gastroenterology at Providence Hospital in Michigan. He previously served as the Associate Program Director of the Henry Ford Gastroenterology and Hepatology fellowship, and continues to be involved in fellow education of IBD across the state of Michigan. He has been recognized for his teaching efforts, high quality care of IBD patients and contributions to patient education. He has presented at ESCCO, AIBD and DDW. He is Vice President of the Interventional IBD Special Interest Group of ASGE. He is President of the Oakland County Medical Society. He is also active on social media including Twitter and Youtube.

Dr. Cheifetz is Director of the Center for Inflammatory Bowel Disease and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology Clerkship Elective and Associate Director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center.
Dr. Cheifetz specializes in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published over 250 articles and chapters on the subject. His research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care. Dr. Cheifetz lectures nationally and internationally on IBD. Dr. Cheifetz is also actively involved in teaching and mentoring medical students, residents, and fellows, and is proud to have trained numerous physicians who now specialize in IBD and direct their own centers.

Dr. Bridget E. Shields is the Susan Nicholas Fasciano Family Foundation Professor of Inflammatory Skin Diseases, Associate Professor, and Director of the Clinical and Translational Research Program in the Department of Dermatology at the University of Wisconsin–Madison. She completed her dermatology residency at the University of Wisconsin, where she served as Chief Resident, followed by a fellowship in Complex Medical Dermatology at the University of Pennsylvania with specialized training in granulomatous skin diseases, including cutaneous Crohn disesae. Dr. Shields directs the University of Wisconsin's specialized IBD-Dermatology clinic and serves on the inpatient dermatology consultation service, caring for patients with complex inflammatory skin disorders. She also leads the University of Wisconsin Multidisciplinary Sarcoidosis Program, fostering collaboration among clinicians and scientists to improve the understanding and treatment of systemic granulomatous disease.
As a clinician-scientist, Dr. Shields' research focuses on defining the molecular mechanisms underlying skin manifestations of IBD through spatial transcriptomics, multiomics, and translational immunology, with the goal of developing precision diagnostics and targeted therapies.
Dr. Shields has authored more than 70 peer-reviewed scientific publications and numerous invited book chapters. She is a nationally recognized speaker who has delivered invited lectures on skin manifestations of IBD and other inflammatory dermatologic disorders at regional and national scientific meetings.
Her research program has been supported by the Dermatology Foundation Medical Dermatology Career Development Award and the Ann Theodore Foundation, among other competitive funding sources.

Oriana M. Damas, MD, MSCTI, is an Associate Professor of Medicine at the University of Miami Miller School of Medicine. She also serves as the Director of Translational Studies for the Crohn’s and Colitis Center. Dr. Damas earned her medical degree from the University of Miami and completed her training in internal medicine and gastroenterology at the University of Miami and Jackson Memorial Hospital.

Her clinical practice and research focus on the care of patients with inflammatory bowel disease (IBD). Dr. Damas has conducted extensive research on environmental factors and the epidemiology of IBD. Her contributions to the field have earned her accolades, including the DREAM Award in recognition of her work with the Hispanic IBD community.

Dr. Damas has significant experience in running clinical trials, including innovative dietary trials, aimed at improving the quality of life for patients with IBD through lifestyle and dietary modifications. She is an NIH-funded researcher and currently serves as the principal investigator for a study developing an anti-inflammatory South Florida diet for IBD patients, which incorporates elements of traditional Latin foods from the region.

She has authored numerous original research articles, and she serves on the Editorial Boards of the prestigious Gastroenterology journal and Crohn’s & Colitis 360. In addition to her research, Dr. Damas is recognized as a national and international leader in her field. She is frequently invited to speak at national and international conferences and is an active member of the AGA n and the Crohn’s & Colitis Foundation.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Jason Schairer is the Director of the Henry Ford IBD Center in Michigan. His interests include Interventional IBD with a focus on stricturotomy, addressing health care inequity, intimacy and sex in IBD, and improving medical education for providers of all levels. He received his medical degree from Wayne Statue University, and went on to complete a fellowship in gastroenterology at Providence Hospital in Michigan. He previously served as the Associate Program Director of the Henry Ford Gastroenterology and Hepatology fellowship, and continues to be involved in fellow education of IBD across the state of Michigan. He has been recognized for his teaching efforts, high quality care of IBD patients and contributions to patient education. He has presented at ESCCO, AIBD and DDW. He is Vice President of the Interventional IBD Special Interest Group of ASGE. He is President of the Oakland County Medical Society. He is also active on social media including Twitter and Youtube.

Maria T. Abreu, MD, is a physician-scientist and gastroenterologist who specializes in inflammatory bowel diseases (IBD). She received her medical degree from the University of Miami School of Medicine and completed a residency in medicine at the Brigham and Women’s Hospital. She served as an Associate Professor of Medicine at Mount Sinai School of Medicine (and head of their IBD Center), a Professor of Medicine and Microbiology & Immunology at the University of Miami School of Medicine (and Director of the Crohn’s and Colitis Center), and currently is the Executive Director of the F. Widjaja IBD Institute at Cedars-Sinai Medical Center; in past years, she has served as the President of the American Gastroenterological Association (AGA) and the Chair of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). Dr. Abreu has 30 years of leadership experience in basic, translational, and clinical research, and has authored almost 300 peer-reviewed articles, book chapters, and reviews. Her work has received multiple awards, including the 2019 Sherman Prize from the Bruce and Cynthia Sherman Charitable Foundation for outstanding achievements in IBD and Healio’s Lifetime Disruptor Award for addressing critical unmet needs in IBD. Her research focuses on interactions between the gut microbiome and the innate immune system in the development of IBD and IBD-associated colon cancer. Currently, Dr. Abreu’s team is investigating how diet may shape the gut microbiome and alleviate IBD symptoms. Understand the underlying mechanisms can help us develop targeted treatment strategies to help patients live their best lives.

Dr. Cheifetz is Director of the Center for Inflammatory Bowel Disease and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology Clerkship Elective and Associate Director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center.
Dr. Cheifetz specializes in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published over 250 articles and chapters on the subject. His research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care. Dr. Cheifetz lectures nationally and internationally on IBD. Dr. Cheifetz is also actively involved in teaching and mentoring medical students, residents, and fellows, and is proud to have trained numerous physicians who now specialize in IBD and direct their own centers.

Dr. Fichera earned his M.D. from the Catholic University of Rome, completed General Surgery Residency at the University of Chicago and two year fellowship in laparoscopic and colorectal surgery at Mt. Sinai School of Medicine in New York. He returned to the University of Chicago where he started and became the first Program Director of the Colon and Rectal Surgery Training Program. He moved to the University of Washington in July 2012 as chief of colorectal surgery and was appointed chief of the section of Gastrointestinal Surgery in 2014 and in 2016 the clinical director of Gastrointestinal Oncology at the Seattle Cancer Care Alliance. In November 2017 he moved to University of North Carolina as the Division Chief of Gastrointestinal Surgery. In September 2019 he became the Division Chief of Colorectal Surgery at Baylor University Medical Center in Dallas, Texas and the Surgery Safety and Quality Officer since July 2020. His clinical and research interest include colorectal cancer and inflammatory bowel disease

Kelly Issokson, MS, RD, CSDH, LDN, CNSC is the Senior Registered Dietitian of Outpatient Nutrition at the University of California, San Francisco (UCSF) and a nationally recognized expert in gastrointestinal nutrition. With over 17 years of clinical experience, she specializes in inflammatory bowel disease (IBD) and surgical nutrition. Ms. Issokson graduated magna cum laude from Johnson & Wales University and earned her MS in Nutrition from California State University, Northridge. She serves on the National Board of the Crohn’s & Colitis Foundation and is a leading voice in advancing nutrition as part of multidisciplinary IBD care. She co-developed the Cedars-Sinai IBD Prehabilitation Program and nutrition education training programs for physicians, APPs, and RDs.

Dr. Amanda Ricciuto completed her medical degree and General Paediatrics training in Montreal at McGill University. She then moved to Toronto to complete fellowship training in Paediatric Gastroenterology at SickKids, including advanced training in the management of paediatric inflammatory bowel disease (IBD). During that time, she obtained a PhD in Clinical Epidemiology and Health Care Research at the Institute of Health Policy, Management and Evaluation at the University of Toronto. Her PhD focused on IBD-associated liver disease, with an emphasis on primary sclerosing cholangitis (PSC).

Areas of Specialty
Dr. Ricciuto’s areas of specialty include paediatric inflammatory bowel disease and IBD-associated liver disease, particularly primary sclerosing cholangitis.

Research Interests
Dr. Ricciuto’s research interests include paediatric IBD generally, as well as the complex inter-relationship between IBD and primary sclerosing cholangitis. Her work has served to better delineate the phenotype of PSC-associated IBD in children and to guide monitoring strategies in this population. From a methodologic standpoint, she has expertise in longitudinal data analysis.

Corey A. Siegel, MD, MS, is the Director of the Walter and Carole Young Center for Digestive Health at the Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire. He is the Constantine and Joyce Hampers Professor of Medicine and a Professor at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.

Dr. Siegel received his medical degree from Tufts University School of Medicine in Boston, Massachusetts. He completed his residency in internal medicine at the Dartmouth Hitchcock Medical Center where he also served as chief medical resident. He then completed a fellowship in Gastroenterology at Dartmouth Hitchcock followed by a fellowship in Inflammatory Bowel Disease at Massachusetts General Hospital in Boston.

Dr. Siegel’s research interests include understanding risk/benefit tradeoffs in IBD, developing models to predict outcomes in Crohn’s disease, creating tools to facilitate shared decision making, expanding telemedicine services to patients with IBD living in rural locations, and improving the quality of care delivered to patients with IBD. He has been funded by the NIH, AHRQ, the Crohn’s and Colitis Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust for this work. Dr. Siegel is the founder of the BRIDGe group, an international research collaborative of IBD investigators. Dr. Siegel was inducted into the International Organization for the Study of IBD (IOIBD) in 2013 and he received the Sherman Prize in 2023. He lives in Hanover, New Hampshire with his wife and three boys.